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4. INTRODUCTION 
Cancer affects people at all ages, but the risk increases with age, and malignant 
tumors accounted for 13% of all deaths worldwide in 2005.1 Endometrial cancer is the 
most common pelvic gynecologic malignancy in industrialized countries, showing an 
increasing incidence rate.2 Even though the majority of endometrial cancers are 
diagnosed at an early stage due to postmenopausal bleeding, 15-20% of the tumors 
recur and might then be unresponsive to systemic therapy.3, 4 Markers to identify 
subgroups of aggressive endometrial cancers are needed to tailor treatment and 
follow-up. 
4.1 ENDOMETRIUM 
The uterus is specifically adapted for the reproductive process and is on a histological 
basis divided into the endometrium and myometrium. The endometrium is a mucosal 
layer composed by glandular epithelium and a highly cellular stroma which undergoes 
cyclic changes of growth, differentiation and shedding in response to ovarian sex 
steroids throughout a woman’s reproductive life. The myometrium surrounds the 
endometrial lining of the uterine cavity and forms the major component of the uterine 
volume.5
4.2 EPIDEMIOLOGY 
In developed countries, endometrial cancer is the most frequent malignant tumor in 
the female genital tract, and the fourth most common cancer after lung, breast and 
colorectal cancer among females.6 Most patients are post-menopausal, and 
approximately 86% of the patients are over 50 years at diagnosis.7 The incidence rate 
in the Norwegian population was 16.5 per 100 000 during 2004-2008 (Figure 1) and 
has increased since the beginning of the 1960’s.8 The incidence of endometrial cancer 
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increases especially in Eastern Asia and some Southern and Eastern European 
countries.9 The mortality rate (per 100 000/year) for cancer in the corpus uteri in 
Norway was 1.7 in 2007 (Figure 1).  
Figure 1.  
Trends in incidence, mortality and five-year relative survival for women with cancer 
in corpus uteri in Norway. 8
4.3 ETIOLOGY 
Approximately 5-10% of endometrial cancer cases have a hereditary basis.10
Hereditary non-polyposis colorectal cancer (HNPCC) is a dominantly inherited 
syndrome due to germline mutations in DNA-mismatch repair genes resulting in 
micro-satellite instability (MSI). Women with HNPCC have a ten-fold increased 
lifetime risk for developing endometrial carcinoma compared to that of the general 
population.11, 12
Several different risk factors are reported for sporadic endometrial cancer, many of 
them include lifestyle factors and unopposed estrogen stimulation. High body mass 
index and diabetes mellitus increase the risk,13, 14 while physical activity reduces the 
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occurence.15 The mechanism behind high body mass index and increased endometrial 
cancer risk is thought to be a disturbed balance between estrogen and progesterone. 
Estrogen produced in fat stores has a mitogenic effect on endometrial cells, and the 
estrogen is not balanced by progesterone in postmenopausal women. This mechanism 
seems to be irrelevant in younger premenopausal women.14 Activity on the other hand 
reduces fat sources, leading to decreased estrogen levels.15 Smoking and oral 
contraception seem to decrease the risk for getting endometrial cancer.16, 17
Endometrial cancers are divided into two clinico-pathological subtypes. Type I, 
including endometrioid endometrial cancers (EECs), is the most common type. It is 
well differentiated, associated with unopposed estrogen exposure or other 
hyperestrogenic risk factors and has a good prognosis.2 Other risk factors for type I 
tumors are obesity, early menarche, late menopause and nulliparity.18 Use of the 
breast cancer drug tamoxifen has been reported to be a risk factor for developing 
endometrial cancer for women older than 50 years.19 Unopposed estrogen therapy and 
tamoxifen both exert proliferative effects on the endometrium.18 Atypical 
	
 
	
 is a known precursor lesion of endometrioid 
adenocarcinoma, and increases the risk for cancer development.20 Type II endometrial 
carcinomas are of the non-endometrioid subtype (serous, clear cell), are poorly 
differentiated, not associated with estrogenic risk factors and have a poorer prognosis 
with a tendency to recur.21 These women are more likely to have a history of 
additional primary tumors, normal weight, multiparity and older age at diagnosis 
compared with patients having type I endometrial cancer.22 
4.4 HISTOPATHOLOGY 
4.4.1 Histological type 
Histologically, 85-90% of endometrial carcinomas are endometrioid 
adenocarcinomas,4 while 10-15% represents the non-endometrioid cancers (NEECs) 
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comprised of serous carcinoma, clear-cell carcinoma and undifferentiated carcinomas. 
They usually arise from atrophic endometrium, have high histological grade and are 
poorly differentiated.2 Carcinosarcomas are a subgroup of endometrial cancer 
composed of an admixture of malignant epithelial and mesenchymal components.23

4.4.2 Histological grade  
Only the EECs are histologically graded in a routine setting, whereas serous and 
clear-cell carcinomas are considered high grade by definition. Histological grading is 
performed according to architecture and adjusted by severe nuclear atypia. Once the 
architectural grade has been established on the basis of the percentage of solid 
growth, notable nuclear atypia raises the grade of the tumor by one.24
4.4.3 Vascular invasion 
Presence of tumor cells in vascular spaces is usually determined on standard H&E 
(hematoxylin and eosin) sections (Figure 2). Vascular invasion is presently not 
integrated into any of the grading system for endometrial cancer, even though it is 
recommended.24 Detection of vascular invasion on standard H&E sections may be 
challenging. Small vessels might be missed, and artificial tissue retraction can be 
mistaken for vascular invasion. Lately, the D2-40 antibody has been used as a specific 
marker for lymphatic vessels.25 D2-40 in combination with CD31 (or CD34) are now 
important markers to distinguish between blood vessels and lymphatic vessels. 
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Figure 2.  
Presence of tumor cells in the vasculature by H&E stained section (magnification x 
400). 
Lymphatic vasculature 
Lymphatic vessels begin as blind ends and are anatomically constructed to permit a 
continuous and rapid removal of transient interstitial fluids, plasma proteins, and cells 
from the interstitium.26 Lymphatic vessels are often found in close contact with blood 
vessels and are present in almost all tissues.27 The lymphatic capillaries consist of a 
single layer of lymphatic endothelial cells that lack tight junctions, basement 
membrane, pericytes and smooth muscle cells and are thought from its structure to be 
easier to penetrate than blood capillaries (Figure 3).  
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Figure 3. 
Lymphatic vessels (in green) start as blind ended and have a more open structure 
than blood vessels (in red) (picture kindly provided by Professor Kari Alitalo).  
Blood vessels 
Blood vessels consist of a single layer of endothelial cells, covered by a vascular 
basement membrane followed by pericytes and smooth muscle cells. Adhesion 
between endothelial cells is mediated by various surface proteins, such as cadherins, 
integrins, immunoglobulins, and proteoglycans.28
4.4.4 Necrosis 
Tumor necrosis is an indicator of fast growing tumors. Tumor cell necrosis was 
defined as areas of necrotic tumor cells bordering viable tumor cells.29  
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4.4.5 Other histopathological features 
Other histopathological factors like solid tumor growth, high mitotic count, 
perivascular lymphocytic infiltration (PLI) and tumor infiltrating lymphocytes (TIL) 
have been reported to be markers of aggressive endometrial cancers.29-32  
4.5 TUMOR BIOLOGY 
Cancer is a group of diseases in which cells show uncontrolled growth, invasion and 
some times metastasis. Cancer development requires accumulation of heritable and 
sporadic changes in gene function. Those changes happen basically in tumor 
suppressor genes that inhibit cell growth and survival (loss of function) and oncogenes 
that promote cell growth and survival (gain of function). Oncogenes may become 
upregulated by gains of chromosomes, gene amplification, translocations and 
activating point mutations. Tumor suppressor genes may be inactivated by loss of 
whole chromosomes, gross deletions, intragenic deletions, point mutations and 
epigenetic silencing.33 Malignant tumors are considered to have the following major 
hallmarks according to Hanahan and Weinberg: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis and ability to invade tissues and metastasize.34
The tumor microenvironment is of critical importance for tumor development and 
metastatic spread, as was suggested by Stephen Paget in 1889 in the “seed and soil” 
hypothesis.35 There is a complex crosstalk between malignant cells and their 
associated stroma in epithelial tumors. Stromal elements consist of extracellular 
matrix (ECM), fibroblasts, inflammatory cells, blood vessels, lymphatic vessels and 
nerves. Secreted factors from the stroma and the neoplastic cells  are known to modify 
tumor cell proliferation, cell motility and alterations of the ECM.36  
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ECM is located outside the cell surface and regulates many aspects of cell behavior in 
addition to providing structural and functional integrity to connective tissues and 
organs. The main components of the ECM are structural proteins (e.g. collagen, 
laminins, fibronectin, vitronectin, elastin), specialized proteins (growth factors, small 
matricellular proteins, small integrin-binding glycoproteins) and proteoglycans. ECM 
is under constant remodeling, especially during tissue development, wound repair, in 
many disease states and in response to infectious agents. Structural changes can be 
induced in response to signals mediated by ECM receptors, by proteolytic cleavage 
(e.g. matrix metalloproteinases (MMPs), serine proteases, cysteine proteases) or by 
tensions (cellular or extracellular).37
Endothelial cells are attached to ECM primarly through integrins on the endothelial 
cell surface. ECM acts like a scaffold supporting endothelial cell structure in addition 
to regulating many processes important for vessel formation. ECM signals regulate a 
molecular balance between vascular morphogenesis and vascular regression. For 
instance, collagens stimulate vascular formation while laminin appears to inhibit the 
formation process,38, 39 and some MMPs control vascular morphogenesis whereas 
other MMPs control regression.40 Degradation of ECM by MMPs creates a path for 
migrating endothelial cells which is an important factor for angiogenesis.41
4.5.1 Genetic factors 
No single genetic alteration has been linked to endometrial cancer, but the genetic 
changes found differ between EECs and NEECs. EECs exhibit more often genetic 
changes as microsatellite instability (MSI), PTEN alternations, mutations in PIK3CA, 
KRAS and CTNNB1 (-catenin) than NEECs. In contrast, NEECs show higher rates of 
genetic alternations such as TP53 mutations, ERBB2 (encoding HER-2) 
amplifications, inactivation of p16 (CDKN2A) and absence E-cadherin (CDH1),42, 43
but overlap exists. 
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Microsatellite instability: Short tandem repeats, microsatellites, are susceptible for 
slippage during DNA replication. Defects in the DNA mismatch repair (MRR) system 
can induce microsatellite instability (MSI), resulting in a higher rate of mutations in 
both coding and non-coding regions.44 The MSI phenotype is detected in 
approximately 20% of non-familiar endometrial cancers, and mainly in the 
endometrioid subtype.45, 46  
Copy-number alterations: LOH and amplification of gene regions have been found 
on several chromosome arms, such as 1p, 3p, 17p, 8p and 10q in endometrial 
cancer.47-50 This indicates regions containing putative tumor suppressor genes and 
oncogenes.  
PTEN encodes a lipid phosphatase which maintains G1 arrest and regulates the 
PI3/AKT pathway.51 An inactive PTEN gives a constantly active PI3K pathway. 
PTEN may be inactivated by combinations of mutations, deletions and loss of 
heterozygosity (LOH).52 Mutations in the tumor suppressor gene PTEN have been 
detected in up to 34-55% of endometrial carcinomas and at a higher frequency among 
the endometrioid tumors.52-54  
PIK3CA is the p110 catalytic subunit of PI3K. PI3K is involved in intracellular 
signaling networks regulating cell proliferation, cellular survival, apoptosis, adhesion 
and motility. PIK3CA somatic mutations are seen in 24-38% of endometrial 
cancers.49, 55
KRAS is a member of the small GTPase superfamily involved in signal transduction 
pathways between cell surface receptors and the nucleus.42 Mutational activation of 
KRAS is observed in 10-30% of endometrial carcinomas.56  
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-catenin: Mutations in CTNNB1, encoding -catenin, have been described in 14-
44% of EEC’s.57 -catenin is an adherence junction protein that maintains cell 
polarity by interactions with E-cadherin, and it is also involved in the Wnt-pathway 
regulating gene transcription.58
TP53 is a tumor suppressor protein that accumulates during DNA damage and trigger 
DNA repair and promotes either cell cycle arrest or apoptosis. Mutation in the TP53
gene gives a protein that accumulates in the nucleus, and increased TP53 expression 
is found in 31-66% of endometrial cancers.59-61 Several studies of endometrial cancer 
show high TP53 expression to be associated with poor prognosis and an aggressive 
phenotype.62-64  
ERBB2 encodes the HER-2 oncogenic growth factor. HER-2 is a transmembrane 
protein that undergoes hetero-dimerization with other HER family members. The 
intracellular tyrosine residues get phosphorylated, and thereby HER-2 induces several 
downstream processes.65 Gene amplification of ERBB2 has been found in about 20% 
of the NEECs but is infrequent in type I cancers.66, 67
P16 is a nuclear protein encoded by the tumor suppressor gene CDKN2A. Loss of p16 
expression has been observed in 14-26% of endometrial cancers.68-70 The underlying 
mechanism of p16 inactivation seems to be promoter hypermethylation, deletions and 
mutations. Promoter hypermethylation is reported in the wide range from 0.7-37%,68, 
69, 71, 72 In contrast, CDKN2A mutations and deletions are reported to be less than 
5%,70, 73, 74 although one study showed a deletion rate of 67%.72
E-cadherin: negative expression of the cell adhesion molecule epithelial cadherin 
was observed in 44-51% of the endometrial cancers and shows association with 
aggressive features.75-77
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4.5.2 Cell cycle regulation 
Genetic abnormalities in cell-cycle regulatory genes can result in uncontrolled 
neoplastic growth. Down-regulation of p27 and Rb2 as well as overexpression of 
CDK4, cyclin A, cyclin B1 and cyclin E are frequently observed in the more 
aggressive tumors. Cyclin D1 overexpression are typically found in endometrioid 
tumors.78  
4.5.3 Apoptosis 
Apoptosis, programmed cell death, is an active process to eliminate unwanted or 
damaged cells. Inhibition of apoptosis gives a longer life-time for the cells, which 
increases the possibility for accumulation of genetic changes and malignant 
transformation. The apoptosis inhibiting protein Bcl-2 has been shown to be 
positively correlated with hormone receptor status in hormone responsive tissue like 
prostate, breast and endometrium.79-81 High Bcl-2 expression shows an association 
with favorable features of endometrial cancer. Apoptosis appears to be decreased in 
endometrial cancer compared with normal endometrium,82, 83 while another study 
showed apoptosis to increase in endometrial cancers compared with normal and 
hyperplastic endometrium.84
4.5.4 Angiogenesis 
Lewis suggested already in 1927 that the tumor environment had an impact on tumor 
growth.85 In 1971, Judah Folkman stated that angiogenesis drives aggressive tumor 
growth and that inhibition of angiogenesis could be a way to block tumor expansion.86
This seminal paper initiated the era of modern angiogenesis research. 
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The term angiogenesis is generally applied to the process of new blood-vessel growth 
from preexisting microvasculature, a process that is coordinated by a range of 
angiogenic factors and inhibitors.87 The process in which a dormant, microscopic and 
non-angiogenic tumor of ~1 mm3 or less turn into a growing angiogenic tumor is a 
process called the angiogenic switch.88, 89 The earliest angiogenic factors, called 
tumor angiogenic factors (TAFs), were isolated from animal tumors and shown to be 
mitogenic for endothelial cells and responsible for formation of new capillaries.90 The 
tumor vasculature is highly heterogeneous and does not have the same morphology as 
normal vasculature.91 Abnormalities involve all components of the vessel wall: 
endothelial cells, basement membrane and the pericytes. Tumor vessels often have 
irregular diameters, abnormal branching patterns, and a defective wall structure. They 
may also have an incomplete vascular basement membrane and an abnormal pericyte 
coat.92 The angiogenic vessels are more accessible to tumor cells than mature vessels 
due to their physical properties.93  
One of the earliest endothelial cell growth factors to be isolated was the basic 
fibroblast growth factor (bFGF).94 A factor secreted from tumor cells called vascular 
permeable factor was isolated by Dvorak’s team and shown to increase the 
permeability of vessels.95 The same factor was later isolated by other groups and 
named vascular endothelial growth factor (VEGF).96 Several potential regulators of 
angiogenesis have later been identified like angiopoietins, aFGF, TGF-, TGF- and 
TNF-.97, 98
4.5.5 Invasion and Metastasis 
Metastasis, the spread of malignant tumors from its primary origin to a new distant 
organ, is the major cause of death for patients with solid malignant tumors. As 
mentioned, Stephen Paget proposed his “seed and soil” theory in 1889.35 He observed 
that metastases did not occur in random organs, since the tumor cells (seed) and the 
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microenvironment of the distant organ (soil) had to be compatible. The metastatic 
process contains several critical steps. First of all, tumor cells must infiltrate the 
surrounding tissue, a process called invasion. Then tumor cells might invade blood or 
lymphatic vessels and must survive attacks from the immune system and forces in the 
vessels. Eventually, cells extravasate and colonize in a secondary organ. However, 
typically less than 0.01% of the tumor cells that reaches the vessels form metastasis.99, 
100 Which kind of vessel a tumor cell manage to invade might be restricted by the 
physical nature of the vessels.99 The invasion process consists of changes in the 
adherence between tumor cells and ECM and other cells. Carcinomas are epithelial 
cells tightly connected to each other by E-cadherin-based cell–cell junctions and are 
initially separated from the stroma by the basement membranes.101 Epithelial–
mesenchymal transition (EMT) is a process where epithelial tumor cells loose their 
junctions to the neighboring cells which allows them to migrate through the basement 
membrane and into the matrix.102 E-cadherin is down-regulated while N-cadherin, 
facilitating the binding between tumor cells and the stroma, is up-regulated.103 Tumor 
cell adherence to the extracellular matrix is mediated by integrin cell surface 
receptors.104 The basement membrane is composed of Type IV collagen, laminin, 
heparan sulfate proteoglycan, entactin, and fibronectin,105 and collagen  (IV) chains 
seems to be lost in the early stages of invasive cancers.106, 107 The matrix degrading 
proteases are upregulated in the ECM and creates a path for the moving tumor 
cells.108 Many cancers express chemokines and chemokine receptors, which all have 
many roles in tumor progression. These cytokines are probably helping the tumor 
cells during invasion rather than being involved in host anti-tumor response.109
4.5.6 Cancer stem cells 
Cancer stem cells (CSC) have the ability to self-renew and to undergo differentiation 
into cells that comprise the bulk of a tumor. It may not be the CSCs that initiate 
tumorigenesis, but over time they might represent the cell population that maintains 
the tumor.110 Stem cells are long-lived cells in many tissues, and early transforming 
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mutations may accumulate in them. Only a minority (11-35% in breast cancer) of the 
cells that comprise a tumor have stem cell-like or tumor forming properties.111
Identification of endometrial stem cells have been difficult due to lack of specific 
markers.112 Still, cells showing properties for epithelial stem cells, progenitor cells 
and CSCs have been found in the endometrium and endometrial cancer.113-115 EZH2, 
a member of the polycomb repressive complex 2, has been considered to play an 
essential role in maintaining self-renewal capacity of hepatic stem/progenitor cells.116
High EZH2 expression in endometrial cancer and other tumors shows an association 
to aggressive features of the cancer and reduced survival.117
BMI-1. 
Conserved heritable cellular memory of chromatin modifications can be maintained 
by the transcriptional activator genes in the trithorax group and the transcriptional 
repressor genes in the polycomb group. Both groups form multiprotein complexes that 
control chromatin accessibility. BMI-1 is a component of the polycomb repressive 
complex 1 which controls gene activity by epigenetic changes like acetylation, 
methylation and mono-ubiquitination of histones, and chromatin methylation.118, 119
BMI-1 seems to be essential for self-renewal of normal and leukaemic haematopoietic 
stem cells, with p16Ink4a and p19Arf as critical downstream effectors.120-122 A BMI-1 
driven signature consisting of 11 genes has been proposed to be a strong prognostic 
factor in many cancers.123 BMI-1 has been associated with a stem cell phenotype and 
aggressive features of some malignant tumors,124-126 and it was therefore of interest to 
see whether this protein was involved in tumor-vascular interactions in endometrial 
cancers. 
4.5.7 Cancer and inflammation 
It has been well documented that several types of inflammation can promote cancer 
development and progression, and up to 20% of all cancers are linked to a chronic 
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infection.127 Examples are persistent Helicobacter Pylori infection and its association 
with gastric cancer and MALT lymphomas, Hepatitis B and C virus infection with 
hepatocellular carcinoma,128 colitis and colon cancer,129 and HPV infection with 
cervical carcinogenesis.130 Also, tumors that epidemiologically are not linked to 
inflammation might have inflammatory components in their microenvironment, and 
inflammation has been suggested to be the seventh hallmark of cancer.131 Typical 
characteristics of cancer initiated inflammation is infiltration of white blood cells, 
mainly tumor associated macrophages, tissue remodeling and angiogenesis.131, 132
Tumor infiltrating immune cells secrete several cytokines that recruit more 
inflammatory cells which might act on all stages of tumorigenesis from initiation of 
mutations with enhanced proliferation to metastatic spread.133 Oncogenic 
transcription factors NF-B and STAT3 are activated by inflammatory cytokines and 
are found in over 50% of all cancers.134  
4.6 GENE EXPRESSION IN ENDOMETRIAL CANCER 
Transcription of DNA into mRNA followed by protein translation is considered the 
central dogma of molecular biology.135 Epigenetic factors that structurally regulate the 
accessibility to DNA segments represent a critical aspect of transcriptional regulation. 
The process from pre-mRNA to a functional mRNA involves many highly regulated 
steps determined by several RNA binding proteins.136 The mRNA is regulated by 
small RNAs in the cytoplasm. MicroRNA (miRNA) was identified 1993 as small 
non-coding RNA molecules that bind to their target mRNA with complementary 
sequence.137 MiRNAs repress protein expression, either by inhibiting the translation 
process or by mRNA degradation.  
Several gene signatures have been presented for endometrial cancer. In 2009, 
Salvesen and collaborators discovered a gene signature distinguishing between two 
major tumor clusters with strikingly different phenotypes,49 and then found the PI3K 
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pathway to be important for aggressive endometrial cancer. Another gene expression 
study of endometrial cancer revealed three distinct clusters showing differences in 
grade and stage, which appear to group tumors with specific clinical behavior.138
Comparison of type I endometrial cancer with normal tissue showed 621 different 
expressed genes that could contribute to the understanding of the biological 
mechanisms.139 Also, a prognosis signature for type I endometrial cancers has been 
presented.140 Even though there are several gene expression signatures correlated with 
endometrial cancer phenotypes, there are none yet applied in the clinical routine for 
handling this patient group. 
MiRNA often shows an altered expression pattern in cancer. Many tumor-suppressors 
and oncogenes seem to be regulated by certain miRNAs. A disturbed expression of 
miRNAs can cause higher expression of tumor oncogenes and lower expression of 
tumor-suppressor genes.141 Also, several miRNA gene expression analyses on 
endometrial cancer have identified miRNA signatures that differ between normal 
endometrium and the cancer, and also among different cancer subtypes.142, 143
4.7 TREATMENT 
Endometrial carcinoma has since 1988 been surgically staged according to the 
International Federation of Gynecology and Obstetretics (FIGO) staging systems, 
revised in 2009.144 Stage I tumors are limited to the corpus, stage II tumors involves 
the cervical stroma, in stage III there is local and/or regional spread of the tumor, and 
stage IV tumors invade the bladder and/or bowel mucosa or carry distant 
metastasis.144 Correct staging is critical for the choice of treatment.  
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4.7.1 Primary surgery 
Early stage I endometrial cancers are treated with hysterectomy with bilateral 
salpingoophorectomy and in some cases removal of lymph nodes. Depending on the 
lymph node status, radiotherapy or chemotherapy is added postoperatively.145 Stage II 
cancers with infiltration of the cervical stroma are treated by radical hysterectomy. 
For more advances stages, the therapy is individualized, depending on tumor burden 
and patient performance status, aiming for removal of the uterus and tumor debulking 
surgery when possible.146 The value of para-aortic lymph node removal is 
controversial, but advocated for high risk endometrial carcinomas with endometrioid 
high grade and non endometrioid carcinomas.147
4.7.2 Adjuvant therapy 
FIGO stage I cancers are categorized from low to high risk. Patients within FIGO 
stage IA and IB (FIGO 1988 criteria) with grade 1and 2 are considered as low risk 
cancers, and those with grade 3 as intermediate cancers. FIGO stage IC with grade 1 
and 2 are considered to be an intermediate subgroup and grade 3 as high risk cancers. 
All FIGO stage I cancers that are papillary serous/clear cell are high risk. Low risk, 
early-stage cancers are effectively treated surgically, commonly without adjuvant 
therapy, and have good prognosis regarding survival.148 A pooled trial containing 905 
women from seven countries with early stage cancers, intermediate or high risk, were 
randomized into groups with surgery alone or with surgery and additional external 
beam radiotherapy.149 After a median follow-up time of 58 months, there was no 
difference in overall survival between the women with or without external beam 
radiotherapy. 
The treatment of high-risk and advanced disease is more complex. Management and 
adjuvant treatment after surgery depends upon patients risk factors for recurrence. 
Options include vaginal brachytherapy, pelvic external-beam radiation therapy and/or 
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chemotherapy. For patients with an intermediate risk for recurrence, there is no 
advantage of adjuvant radiotherapy in randomized trials.150-152 Women with advanced 
stage-disease have a poor survival and high risk for recurrence. There are no 
prospective randomized trials that show adjuvant radiation to improve survival in this 
group.153 Some studies indicate that radiation combined with chemotherapy might 
improve overall survival in patients with endometrial cancers,154, 155 while another 
study did not show chemotherapy to improve overall survival or decrease the 
recurrence rate.156 Randomized trials show no survival benefit from adjuvant 
hormonal treatment.157, 158
Patients with recurrent and metastatic disease may be treated with radiotherapy, 
surgery, endocrine therapy and chemotherapy. Patients with localized pelvic 
recurrences should be evaluated for surgery at relapse,159 or can be treated with pelvic 
radiotherapy if they have not previously received pelvic irradiation.160 Systemic 
treatment is palliative, and response to treatment is generally partial and last for an 
average of 3-6 months. Response to hormonal treatment is best for receptor positive 
tumors.161 Chemotherapy has a limited place in the management of advanced or 
recurrent endometrial cancer. Recent chemotherapy trials in advanced endometrial 
cancer have focused on a combination of agents that have shown effects as single 
agents.161, 162
4.7.3 Clinical trials 
There are ongoing clinical trials, based on molecular mechanisms, to identify novel 
targeted therapy.163 These studies are designed mainly for advanced or recurrent 
endometrial cancers. Against angiogenesis, humanized mAbs that binds and inhibit 
VEGF have been designed (e.g. bevacizumab and VEGF-TRAP), or small molecule 
inhibitors targeting VEGF receptors (e.g. sorafenib and sunitinib) may be an option. 
Loss of PTEN results in activation of AKT followed by upregulation of mTOR 
activity. Therefore, tumors with loss of PTEN might be candidates for mTOR 
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inhibitors temsirolimus, everolimus and deforolimus. There are several drugs 
targeting the EGFR family, e.g. lapatinib, targeting booth EGFR and HER-2, and 
gefitinib.164 Hormonal receptor PR is an important target and also aromatase 
inhibitors against estrogen synthesis, e.g. letrozole.165 TP53, PIK3CA, new ER 
antagonists and transmembrane tight junction proteins claudins have been proposed to 
be potential targets.165, 166
4.8 PROGNOSIS 
The EUROCARE database, based on cancer registries from 17 European countries, 
shows a 5-year survival of 75% for endometrial cancer patients.167 Decrease of 
incidence and mortality of endometrial cancer is unlikely in the next few years, as 
early detection and treatment modalities have not been proven to have a major impact 
on mortality.145
4.8.1 Clinical factors 
Age 
Younger women with endometrial cancer generally have a better prognosis than older 
women (Figure 4).8 Histological grade and in particular depth of myometrial invasion 
appear to increase with age. The observed poorer prognosis at higher age may to some 
degree relate to a lack of surgical staging in these individuals and also less aggressive 
therapy postoperatively.168
27
Figure 4.  
Relative survival according to age at diagnosis among women with endometrial 
cancer. 8
FIGO stage 
The survival of patients with cancer in the corpus uteri decreases dramatically from 
stage IA with a five year survival between 91-100% to stage IV with a five year 
survival of 0-22% (FIGO 1988 criteria).30, 168-170
4.8.2 Histopathological factors 
Histological type  
The endometrioid endometrial carcinomas have a 75-83% 5-year survival while the 
non-endometrioid carcinomas only have 35-45% 5-year survival.2, 3, 168, 171
Histological grade 
Grade and depth of myometrial infiltration is related to the risk of metastatic 
spread.168 The five year survival in grade 1 is between 96-98% and decreases to 58-
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76% in grade 3.30, 170, 172 In all stages of endometrial cancer, grade 2 gives a hazard 
ratio between 1.3-1.6 and grade 3 a hazard ratio between 2.1-2.6.168 Univariate 
survival analysis also show histological grade to be significantly associated with 
survival.30, 173
Myometrial infiltration 
The depth of myometrial invasion in patients with endometrial cancer correlates 
strongly with the prevalence of lymph node metastasis and with patient survival.30, 173, 
174 Patients with more than 50% myometrial invasion are at marked risk for 
extrauterine metastases, including pelvic and para-aortic lymph node metastases 175. 
Tumors with myometrial invasion below 50% have less than 5% prevalence of nodal 
spread.176
Vascular invasion 
Vascular invasion has shown to be a marker of unfavorable prognosis in endometrial 
cancer and associated with several aggressive clinico-pathological features.30, 177, 178
The antibody D2-40 is reported to be a good lymphatic vessel marker and has allowed 
studies on specific vascular invasion in many cancers like breast, colorectal, oral 
squamous cell and renal cell carcinoma, and shows in those cancers associations with 
aggressive features.179-182 High lymphatic vessel density shows associations with 
several aggressive characteristics including vascular invasion in endometrial 
cancer.183
Necrosis 
Several types of cancers with presence of necrosis show a correlation with increased 
angiogenesis in tumors and poor prognosis.184-187 Presence of necrosis in endometrial 
cancer is of prognostic importance.30, 172
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4.8.3 Other histopathological features 
In endometrial cancer, the growth patterns show conflicting results regarding 
implications for prognosis.30, 172, 188 Increased solid growth is of strong prognostic 
importance, both by univariate and multivariate analysis.30, 172, 188 High mitotic count 
is also an indicator of poor prognosis of endometrial cancer.30, 188 Presence of CD8+
and CD45R0+ TIL shows associations to favorable prognostic markers and disease 
specific survival in endometrial cancer,189 and also in other types of cancers.190 In 
endometrial cancer, PLI shows an association to vascular invasion.191
4.8.4 Biological markers 
Steroid hormone receptors 
Endometrial cell proliferation is under control of both estrogen and progesterone. 
Expression of estrogen- and progesterone receptors (ER, PR) is shown to have a 
favorable prognosis in patients with endometrial cancer.192, 193  
DNA ploidy 
A normal cell is diploid and contains one set of chromosomes from each parent, while 
an aneuploid cell is having an abnormal number of chromosomes. Flow cytometric 
analysis of DNA ploidy shows that aneuploidy is associated with poor prognosis in 
endometrial cancer.194, 195
Oncogenes and tumor suppressor genes 
Mutations in the PTEN tumor suppressor gene leading to gene inactivation is found in 
20-80% of endometrial carcinomas, most of them in the endometrioid subtype. The 
presence of mutations in hyperplasia indicates that this is an early event in 
endometrial carcinogenesis,196-198 and mutations and loss of PTEN show associations 
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with a good prognosis.54, 199-201 In contrast, others show that loss of PTEN is 
associated with poor prognosis.202, 203 KRAS mutations have been reported in 10-30% 
of endometrial cancers.57 Most studies do not find any association between KRAS
mutations and clinico-pathological factors,204-206 although one study reports mutations 
in KRAS to be associated with favorable prognosis.207 HER-2 status has been shown 
to be an independent prognostic marker in endometrial cancer, and of particular 
importance in high-risk tumors in several studies,66, 208, 209 while other studies do not 
find HER-2 to be an independent prognostic marker.210, 211 TP53, regulating cell cycle 
progression by transcriptional activation of different genes, is described to be an 
independent prognostic factor in endometrial cancer,63, 212 and to be associated with 
unfavorable clinico-pathological features.203, 213, 214 Inactivation of p16, caused by 
LOH, deletions, point mutations or promoter hypermethylation, is thought to be 
involved in tumor progression and poor prognosis,68, 69 and to be associated with 
aggressive phenotypes in endometrial cancer.212 Whether MSI is a prognostic factor is 
not clear. Some studies show better survival for MSI positive endometrial carcinomas 
as well as an association with the endometrioid subtype,215 while another study 
indicated poorer prognosis for MSI positive tumors,216 and others did not show any 
relation between MSI and survival.217-219
Cell cycle related proteins 
Multiple cell cycle regulators have been reported in endometrial cancer, but only a 
few of them seem to be of clear prognostic value.220, 221 Still, high cyclin A expression 
in one study exhibited an association to unfavorable prognosis.221 The cell 
proliferation marker Ki67 is positive in all phases of the cell cycle except of and has 
been shown to be a robust marker for poor prognosis in endometrial cancer.63
Apoptosis related proteins 
Bcl-2 seems to be more strongly expressed in hyperplasias and low grade endometrial 
carcinoma,222, 223 which may indicate that Bcl-2 play a more prominent role in early 
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rather than in the late phases. Loss of Bcl-2 is shown to be a factor indicating poor 
prognosis,224 and overexpression is thus correlated with good prognosis in 
endometrial cancer.225
Angiogenesis 
Intratumoral microvessel density is thought to reflect the angiogenic activity of 
malignant tumors. High microvessel density (MVD), the total amount of microvessels 
in a defined area as well as immature vessels, relate to aggressive phenotypes and is 
of significant prognostic value in endometrial cancer.63, 183, 226-228 Also, an increased 
MVD from endometrial hyperplasia to endometrial cancer has been observed.229
MVD as a marker for aggressive tumors has been demonstrated in several other 
cancer types.230, 231 High expression of the vascular endothelial growth factor VEGF 
is shown to indicate a poor outcome in endometrial cancer.227, 232 Alterations in the 
microvasculature pattern termed glomeruloid microvascular proliferations (GMP) or 
glomeruloid bodies (GB) might also indicate an activated angiogenesis and is 
probably related to VEGF stimulation.233, 234 Studies of different human tumors, 
among them endometrial cancer, show GMP to be a prognostic marker of survival.235
Vascular proliferation is another very promising indicator of active angiogenesis and 
poor prognosis in endometrial cancer, even stronger than GMP and MVD.183  
Molecules associated with cell adhesion and stromal invasion  
Loss of -catenin has been found to be an independent prognostic factor for 
unfavorable prognosis in endometrial cancer,203, 236 especially in tumors with a 
favorable histological subtype. In contrast, another report did not find any association 
between -catenin and prognosis.237 Decreased E-cadherin expression is a marker of 
tumor progression, survival and distant metastasis.237-239 P-cadherin as well as a 
switch from E- to P-cadherin expression, possible as an indication of EMT, is shown 
to be a prognostic factor in endometrial cancer.236
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There is still a need for new and better prognostic and predictive markers, and there 
are several molecules that have so far not been investigated among endometrial 
cancer patients. Lipocalin 2 is a molecule that is shown to be associated with several 
cancers,240-243 including ER- and PR-negative breast tumors.244 Elevated levels of 
LCN2 have been observed in plasma and serum during various physiological and 
pathological conditions, such as metastatic breast and colorectal cancer, acute kidney 
injury, pancreatitis and preeclampsia.245-247 Studies of breast and colon carcinoma cell 
lines propose that LCN2 is involved in the EMT process.243, 248
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5. BACKGROUND AND AIMS OF THE STUDY 
Presence of vascular invasion, i.e. tumor cells entering vascular channels, is a 
significant prognostic factor in several cancers.181, 249-251 Stefansson et al. previously 
showed that vascular invasion was a strong prognostic marker in endometrial 
cancer.30 We here wanted to further investigate the biology involved in vascular 
invasion. An improved understanding of this process might contribute to potential 
markers of metastatic spread and may provide clinically important information for 
better management of endometrial cancer. We also wanted to study a selection of 
tumor markers and genetic signatures with respect to the aggressive phenotype of 
endometrial cancer. Identifying new and sensitive molecular markers could provide a 
more optimal basis for individual treatment and increase our understanding of the 
tumor biology.  
5.1 SPECIFIC AIMS 
1. In Paper I, the aim was to evaluate the frequency of specific vascular invasion, i.e. 
lymphatic or blood vascular invasion, and their relation to clinico-pathological 
variables and prognosis in endometrial cancer.  
2. In Paper II, the aim was to explore gene signatures identifying tumors with 
vascular invasion and to further validate selected candidate markers with 
immunohistochemical staining. 
3. In Paper III, the aim was to investigate the relationship between candidate stem 
cell marker BMI-1, as well as a BMI-1 associated gene expression signature, with 
features of aggressive endometrial cancer including vascular invasion. 
34
4. In Paper IV, the aim was to examine the prognostic implication of LCN2 
expression in endometrial cancer in relation to EMT markers, angiogenesis, vascular 
invasion and patient survival.  
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6. MATERIALS AND METHODS 
6.1 MATERIALS 
Hordaland County has about 460 000 inhabitants representing around 10% of the total 
Norwegian population. Two independent populations based endometrial cancer series 
were used in this study. They have been collected at the Department of Gynecology 
and Obstetrics, Haukeland University Hospital and University of Bergen, Norway. 
6.1.1 Retrospective series 
The retrospective series, containing 316 patients, include all patients diagnosed with 
primary endometrial cancer during 1981-1990. Patients were followed from the time 
of primary surgery until death or last follow up in 2007. The median follow-up time 
for the survivors was 17 years (range 6-23 years). This series is well documented 
concerning clinico-pathological and follow-up information.68, 252 The series consists 
of paraffin embedded material, both in standard blocks and tissue microarray (TMA) 
blocks, which have been used for immunohistochemical studies. Of all 316 patients, 
12 were excluded due to a changed diagnosis and 5 due to a diagnosis based on 
cytological examination only with no available histological material.63 Of the 
remaining 299 cases, sufficient tumor materials in primary blocks were available for 
286 patients. In Paper I, whole sections with deeply infiltrating tumors were 
available for 276 tumors (97%). In Paper II, Paper III and Paper IV, 254-261 (89-
91%), 264 (92%) and 256 (90%) tumors had sufficient quality and quantity for IHC 
registration present on TMA sections.  
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6.1.2 Prospective series 
The prospective series contains 57 fresh frozen cases and in parallel paraffin 
embedded primary endometrial tumors that were prospective collected during 2001-
2003. The patients were followed from time of primary surgery until September 2008 
or until death. Median follow-up time for survivors was 5.1 years (range 0.6-7 years).
Fresh tumor tissue was carefully dissected from the surgical specimens and divided in 
two parts: one part was immediately frozen in liquid nitrogen and stored for later use 
at -80oC; the other half was fixed in formalin and paraffin embedded for histological 
examination. H&E stained sections were examined by a pathologist for the tumor 
fraction. The tissues contained a minimum of 50% tumor cells, but the majority had 
>80% tumor cells. These 57 samples were selected at random from a population 
based tissue bank of gynecologic cancers and have been used for gene expression 
studies in Paper II and Paper III. All patients were surgically staged according to the 
FIGO 1988 criteria. 
6.2 METHODS 
6.2.1 Protein expression studies  
Immunohistochemistry 
Immunohistochemistry (IHC) was performed on 5 µm sections of formalin-fixed and 
paraffin embedded tumor samples. The sections were deparaffinized in xylene and 
rehydrated in alcohol with decreasing alcohol concentration. During formalin-
fixation, covalent chemical bonds between the proteins are created. These bonds can 
mask the target for antibody binding making detection difficult. Epitope retrieval can 
be achieved enzymatically (e.g. proteinase K, pepsin, trypsin, etc) or by heat. The 
method used in this study was microwave retrieval treatment in different buffers. 
Immunohistochemistry protocols for the different antibodies are listed in Table 2.  
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Table 2. Immunohistochemical protocols
  
aMicrowave, b10 mM citrate buffer, dTarget retrievel solution, cCatalyzed Signal Amplification 
system (Dako), eDilution on regular slides, others TMA-sections, fTris-EDTA (5 vs 0.5mM), gPower 
vision Poly-HRP anti-goat IgG, hPre-blocked with goat serum diluted 1:4. 
Tissue microarray (TMA)
A TMA block contains several cores of tissue that is punched from selected areas in a 
donor tissue block and then placed in a recipient TMA block. The TMA arrays used 
in Paper II-IV contains tissue cylinders of 0.6 mm in triplicate from each tumor. 
Whole tumor sections are stained by H&E, and areas with high cellularity and the 
Biomarker Antigen retrievel Dilution Incubation Detection 
ANGPTL4 
Sigma 
MWa 20 min,  
citrate bufferb pH 6.0 
1:15 60 min, RT Envision 
BMI-1 
Upstate, 05-637, Clone F6 
MW 15 min,  
TE buffer pH 9.0 
1:800 O/N, 4°C Envision 
BMI-1  
From Dr Arie P. Otte 
MW 20 min,  
TE buffer pH 9.0 
1:1 60 min, RT CSA-kitc
CD-31 
Dako, M0823
MW 20 min, 
TRSd pH 6.0
1:25 60 min, RT Envision 
Collagen type VIII 
Cosmo Bio LTD 
MW 20 min,  
citrate buffer pH 6.0 
1:250/1:100e 60 min, RT Envision 
D2-40  
Dako, M3619 
MW 15 min,  
TEf buffer pH 9.0
1:100 30 min, RT Envision 
IL8 
R&D 
MW 20 min,  
TRS pH 6.0 
1:50 O/N, 4°C PVP-HRPg
MMP3 
Calbiochem 
MW 20 min,  
citrate buffer pH 6.0 
1:40/1:20e O/N, 4°C Envision 
N-cadherin 
Dako, M3613 
MW 20 min, 
TE buffer pH 9.0 
1:25 60 min, RT Envision 
Lipocalin 2 
R&D, MAB1757 
MW 15 min, 
citrate buffer pH 6.0 
1:25h 60 min, RT 1:300, goat anti-
rat IgG HRP 
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highest grade are identified by a pathologist and selected for the TMA block. This 
method was introduced by Kononen and collaborators in 1998.253  
Staining index 
Immunohistochemical staining was evaluated on whole tumor tissue slides and TMA 
sections using a semi-quantitative and subjective grading system taking into account 
both staining intensity and proportion of cells showing staining. Each slide was 
evaluated in a standard light microscope for immunohistochemical staining by 2 of 
the authors which were blinded for both clinico-pathological and follow-up 
information. A staining index (SI) was calculated as a product of the staining intensity 
(0; no staining, 1; weak staining, 2; medium staining and 3; strong staining) and 
positive area (1: <10%, 2: 10-50%, 3: >50%), giving a SI between 0-9. Cases were 
divided in two or three groups based on median or quartiles for the staining index, 
also considering the size of these groups, number of events and survival similarities.  
Assessment of specific vascular invasion 
Detection of tumor cells within vascular spaces is usually done on standard H&E 
stained sections. By using the antibodies D2-40 and CD31, it is possible to 
differentiate vascular invasion into blood or lymphatic vascular invasion. CD31 does 
not bind completely specific to blood vessel endothelia but might also show weak 
staining in lymphatic endothelium.254 Blood vascular invasion was considered when 
the vessel with tumor cells showed positive staining for CD31, while the same vessel 
was negative for D2-40. Lymphatic vascular invasion was assessed when tumor cells 
had invaded a vessel positive for D2-40. The classification of specific vascular 
invasion was done on whole tumor sections showing the deepest infiltration of tumor 
cells. Two of the 102 positive cases based on H&E-slides, had different tumor blocks 
examined by IHC in Paper I.  
39
Western blot 
Western blot was used to investigate whether the antibodies used for 
immunohistochemistry indicated a specific staining.  
6.2.2 Gene expression studies 
Gene expression studies are of significant interest for many fields of biological 
research. The expression of genes might give insight into regulatory networks and 
lead to identification of genes relevant for biological processes.  
cDNA and oligonucleotide microarray analysis 
Total RNA is reversely transcribed into cDNA and thereafter amplified to cRNA 
(complementary RNA) with incorporation of fluorescently labeled ribonucleotides 
during the enzymatic amplification. The labeled cRNAs hybridize to complementary 
probes printed on the microarray slide with a frequency proportional to their relative 
abundance. After hybridization and stringent washing at optimized conditions, the 
amount of bound probes to each spot is scanned. Replicates of the microarray 
experiment was performed to show reliable and reproducible results.255 Both one and 
two channel systems were used. In the two-channel system, the samples compared, 
i.e. tumor versus control, were labeled with two different fluorescent dyes. Cy3 and 
Cy5, often used for microarrays, emit green light and red light, respectively, when 
excited by incoming light of appropriate wavelengths. When Cy3-labeled and Cy5-
labelled cRNAs from two different samples are mixed in equal amounts and 
hybridized to the microarray slide, the relative green and red light intensities generate 
a ratio that tells which gene is relatively up- or down-regulated.256 In the one-channel 
system, only one dye is used, and only one sample is hybridized to each microarray 
slide. Here, the absolute level of gene expression is calculated based upon a defined 
background signal and computer based normalization procedures. In the two-channel 
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studies, either the Universal Human Reference RNA obtained from Stratagene or an 
in-house pool of RNA prepared from 18 different cell lines were used for reference. 
The largest available Agilent 44k oligonucleotide arrays were used and inter-array 
validation was achieved by the less comprehensive Agilent 21k and 22k microarrays. 
qPCR 
Candidate genes generated by SAM (Significance Analysis of Microarrays) in 
addition to hypothesis based genes were confirmed by real-time quantitative PCR 
(qPCR) with TaqMan Low Density Arrays (TLDA). We also adopted a 
supplementary approach to identify genes of interest from the microarray 
experiments. A list of 287 genes, compiled from the literature and having a known 
relationship with angiogenesis and invasion, was used. Individual genes were ranked 
by their combined associations with vascular invasion, mitosis, tumor cell necrosis, 
FIGO stage and metastatic phenotype. Genes with the lowest combined p-value 
(product of individual p-values) were further analyzed by qPCR. The idea when using 
this additional method was to identify genes associated with aggressive endometrial 
carcinoma subgroups. TLDA are microfluidic cards containing 384 wells per card. 
Each well contains specific, user-defined primers and probes, detecting a single gene. 
Of the 35 genes generated from SAM, 30 genes were identified with TaqMan assays 
at Applied Biosystems. A total of 87 genes in duplicate in addition to the control 
genes ACTB and GAPDH were analyzed with qPCR.  
Bioinformatics
Microarray experiments give rise to expression data of thousands of genes, and it 
might be challenging to extract meaningful biological information.257 The expression 
data must be pre-processed, and background intensity and spots with low signals that 
can not be distinguished from the background must be removed. Normalization must 
be done to eliminate systematic variation in intensity, which is not due to actual 
differences in gene expression.258 The lowess normalization method (Paper II)
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corrects for dye-specific effects and assume that most genes would have unchanged 
expression levels and are expected to be centered around zero.259 Genes that do not 
show reliable values in more than 70% of the samples and have an intensity of less 
than 2SE (standard error) over the background, or have saturated spots were filtered. 
Missing values in the filtered dataset were predicted using LSimpute adaptive.260 This 
method uses correlations between genes to replace missing values, e.g. cellular co-
regulation of genes in functional processes. In Paper II, differences in gene 
expression of 57 tumors related to vascular invasion were investigated. An 
appropriate significance threshold value was needed. We used a threshold value with 
a minimum fold change of 2.0 and the Significance Analysis of Microarrays (SAM) to 
identify changes in gene expression that are biologically and statistically 
significant.261 Briefly, SAM uses a gene specific t-test, and each gene is assigned a 
score due to its change in gene expression relative to the standard deviation of 
repeated measurements for that gene. 
The predictable strength of the constructed gene signature in relation to vascular 
invasion was tested using Leave-one-out-cross-validation (LOOCV). One sample is 
kept out in each round and a classifier is made of the remaining samples. The 
classifier changes each round due to the different samples in the training set. The 
classifier is tested on the outsider, and the predicted result is compared to the true 
status and a false discovery rate is constructed. Forward selection and backward 
elimination are two statistical methods used for constructing condensed predictor 
gene sets out of the originally gene signature.  
Cell cultures 
In vivo, tumor cells are known to influence blood and lymphatic vessels during the 
metastasis process. Many of the interactions may take place by soluble factors such as 
cytokines, including several pro- and anti-angiogenic mediators. In Paper II, we 
wanted to investigate if endothelial cells in vitro, stimulated by conditioned medium 
42
from endometrial tumor cells, showed any up- or down-regulated genes with special 
focus on candidates from the vascular invasion signature. Seven different endometrial 
cancer cell lines were cultured, the media were centrifuged and the supernatant was 
referred to as conditioned media. Endothelial cell lines HUVEC and HMVEC were 
then exposed to conditioned media for 18 hours. RNA was purified and gene 
expression was detected by microarray analysis. The focus of this study was to 
examine possible alterations in the expression levels of our up-regulated candidate 
genes from the vascular invasion signature, induced by the influence of tumor cells on 
the endothelium.  
6.2.3 Statistical methods 
Comparison of categorical variables was done with Pearson’s Chi-square test. 
Univariate survival analysis was performed by the product-limit method (Kaplan-
Meier method), using the log-rank test for differences between subgroups. 
Multivariate survival analysis was performed with Cox’ proportional hazards method 
and the likelihood ratio test (Lratio). The time of primary operation was used as the 
entry date, and death from endometrial cancer was the end-point. All statistical 
analyses performed in Paper I-IV were performed with the SPSS software package 
version 15.0 or PASW statistical software package version 17. Statistical analyses in 
Paper II-III related to gene expression were done with the software J-Express or 
SDS 2.2.  
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7. MAIN RESULTS 
Paper I 
Specific vascular invasion, i.e. whether tumor cells are present in lymphatic or blood 
vessels, was determined by using antibodies CD31 and D2-40 on 276 endometrial 
cancers in the retrospective series. Univariate survival analysis revealed that patients 
with blood vessels invaded by tumor cells seem to have the worst prognosis, whereas 
patients with lymphatic vessels invaded have an intermediate prognosis. Patients 
without vascular invasion had the best prognosis. The same was seen when using 
recurrence free survival. Multivariate survival analysis showed blood vascular 
invasion to be a strong and independent prognostic factor together with the standard 
variables histological type, histological grade and FIGO stage. This was seen among 
all cases as well as for the endometrioid subtype. Our data suggest that 
haematogenous spread indicates a more aggressive subgroup of endometrial cancers.  
Paper II
Gene expression patterns in 57 endometrial cancers from our prospective series were 
analyzed with microarrays and qPCR in relation to vascular invasion. A vascular 
invasion signature (VIS), expressing differences with respect to vascular invasion, 
was found to be prognostically significant by univariate analysis, although not by 
multivariate analysis. Published gene signatures relevant for tumor progression were 
also examined. By hierarchical clustering, signatures for endothelial cells, wound 
response, TGF- and a VEGF-signature were significantly related to vascular 
invasion.  
Single gene candidates including ANGPTL4, COL8A1, IL8 and MMP3, all being 
upregulated with vascular invasion, were examined by IHC. Weak or no expression 
for ANGPTL4 and IL8 was associated with reduced survival. Collagen type VIII and 
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MMP3 were co-expressed in tumor cells and were both associated with vascular 
invasion at the protein level. Endothelial cells stimulated with conditioned media 
from endometrial tumor cells showed an up-regulation of ANGPTL4 and MMP3. 
Paper III
BMI-1, a candidate stem cell marker, is a member of the polycomb group and has 
been reported to be elevated in several cancers, both at protein and mRNA levels. A 
BMI-1 driven signature consisting of 11 genes has also been reported to be a 
prognostic signature for many cancers.123 Our microarray data contained 9 of these 11 
genes. Low BMI-1 mRNA expression was significantly associated with the presence 
of vascular invasion and high histological grade Also, a significant correlation 
between low mRNA levels of BMI-1 and loss of ER and PR expression was shown. 
Tumors with a lower BMI-1 protein expression were associated with the presence of 
vascular invasion, deep myometrial infiltration and loss of ER and PR staining. 
Importantly, BMI-1 mRNA levels were significantly associated with BMI-1 protein 
expression, whereas the 9-gene signature showed an inverse correlation to BMI-1, 
ER and PR mRNA expression. The signature was significantly associated with non-
endometrioid subtype, high histological grade, vascular invasion and poor patient 
prognosis in our endometrial cancer series.  
Paper IV 
In our retrospective series, strong LCN2 expression was associated with non-
endometrioid endometrial carcinomas, nuclear grade 3, >50% solid growth and 
ER/PR negativity. There was no association with EMT-markers (P-cadhein, N-
cadherin, E-cadherin and -catenin). Of the angiogenesis markers, VEGF-A showed a 
significant relationship with LCN2 expression. Regarding prognosis, cases with no 
LCN2 staining had the best survival, cases with medium staining showed an 
intermediate survival, while the small subgroup of patients showing strong LCN2 
expression had a significantly worse prognosis.  
45
8. DISCUSSION 
8.1 DISCUSSION OF MATERIALS AND METHODS 
8.1.1 Patient series 
As described in the Materials and Methods section, the population based retrospective 
series used in Paper I-IV includes all women diagnosed with primary endometrial 
carcinomas in Hordaland County during 1981-1990. This is a well documented series 
with a long follow-up time, and the series has been used in approximately 30 
published research articles. The tumor material in this series was retrospectively 
collected from the archives at the Department of Pathology, Haukeland University 
Hospital. This archive contains formalin-fixed and paraffin embedded tissue blocks 
and original slides. This makes it possible to collect large series with long follow-up, 
which is invaluable in research. Variation in perioperative tissue handling, e.g. delay 
of fixation and fixation time may affect the sensitivity of immunohistochemical 
methods. For instance, delayed formalin fixation has a negative effect on ER and PR 
staining in breast cancer.262
The prospective series contains 57 fresh frozen endometrial carcinomas, 22 with 
vascular invasion and 35 without, and randomly collected during the period 2001-
2003. To account for a possible selection bias in the prospective series, a panel of 
standard variables was compared with the retrospective population based patient 
series. No significantly differences were found for vascular invasion, histological 
subtype, histological grade, necrosis, mitosis and FIGO stage (Table 1). 
For gene expression studies done in Paper II-III, mRNA of good quality was needed. 
Tissue handling of fresh material is important, since mRNA starts to degrade by 
RNase enzymes within the first hour after surgical removal if the tissue is not frozen 
rapidly.263All endometrial tumors used for expression studies in Paper II-III
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contained at least 50% tumor cells, and the majority of them contained more than 
80%.  
Table 1. Patient characteristics for the prospective and retrospective series
aPearson Chi-Square, bNS= no significant difference between the prospective test series and the 
retrospective validation series for the respective variable, cEndometrioid endometrial cancer, dNon-
endometrioid endometrial cancer, eMedian values used as cut-off point, fData for one patient is 
missing in the retrospective validation series 
8.1.2 Gene expression studies 
Microarray analysis is a powerful method allowing investigation of gene expression 
patterns of thousands of genes at the same time. To obtain a successful microarray 
experiment, it is important that all processes from the beginning to the end are 
optimimal.264 The purity of RNA is important to avoid non-specific signals, and fresh 
Variable  Prospective series
N (%) 
Retrospective series
N (%) 
p-valuea
Vascular invasion Absent 35 (61) 183 (64) NSb
 Present 22 (39) 103 (36)
Histological subtype EECc 51 (89) 257 (90) NS 
 NEECd 6 (11) 29 (10)
Histological grade 1 and 2 44 (77) 177 (62) NS 
 3 13 (23) 109 (38)
Necrosis Absent 22 (39) 119 (42) NS 
 Present 35 (61) 167 (58)
Mitosise Low 42 (74) 216 (76) NS 
 High 15 (26) 70 (24)
FIGO stagef I/II 48 (84) 230 (81) NS 
 III/IV 9 (16) 55 (19)
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material is absolutely preferable compared to fixed tissues.265 Formalin fixed and 
paraffin embedded material usually contains degraded mRNA which is difficult to 
recover in a quantitative way.266 When making cDNA (complementary DNA), total 
RNA or purified mRNA can be used. However, only 5% or even much less of the 
total RNA is mRNA. Therefore, non-specific cross hybridization might be expected 
when total RNA is used as a source of labeled target nucleic acids in microarray 
hybridizations. A study comparing either purified total RNA and mRNA 
(poly(A)RNA) in both two- and one-channel detection platforms demonstrated, 
nevertheless, that using total RNA as input to microarray hybridizations generated 
equally good results as using poly(A)RNA.267 This observation was important to save 
both materials and labor during microarray studies. Total RNA was purified and 
reversely transcribed into cDNA by using random hexamers and the M-MLV enzyme. 
Oligo (dT) primers, specific primers and random hexamers are the most common 
primers used in the reverse transcriptase synthesis of cDNA. Random hexamers have 
been shown to give the best representation of all mRNA sequences.268
Confirmation of microarray gene expression 
Confirmation of microarray gene expression results is desirable, and we consider 
qPCR to be the method most relevant for small-scale validation. Many commercial 
assays are available, and the method is not too time consuming and does not require 
large amounts of RNA. The linear dynamic range is much higher for qPCR than for 
microarray analysis, and as a result more compressed fold changes are usually 
obtained based upon microarray data compared to qPCR data. P-value, FDR and fold 
change can be used to validate gene expression data, but questions still remain 
regarding which values should be used. If qPCR data do not validate the microarray 
results, should one assume that qPCR gives a more true result than microarrays and 
eliminate that gene?269-272 We here decided to use qPCR analysis as end-point, and 
genes not significant for vascular invasion were excluded. The same cut-point as we 
used for SAM was also applied for qPCR (fold change 2.0; p<0.05).
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Normalization is needed to compensate for differences in the amount of biological 
material and can be done by several methods. The most common technique is to use 
an internal reference gene that is assumed to be expressed at a constant level. The 
problem is to find a gene with small variations between samples. A reference gene 
with stable expression in one organ may not be suitable for normalization of gene 
expression in another.273 Thus, for the qPCR validation study, we used two internal 
control genes, ACTB and GAPDH.  
A summary score of the vascular invasion gene signature was found for each patient 
by summarizing the normalized expression values for up-regulated genes and 
subtracting the sum of down-regulated genes. Linear regression was used to test for 
correlations between the microarray generated versus qPCR generated vascular 
invasion signatures. The two gene expression techniques, with GAPDH as reference 
gene for qPCR, were strongly correlated (r=0.93). The strong correlation indicates 
that GAPDH was a suitable reference gene for our endometrial cancer samples. 
Probably, the most optimal would have been to use a set of internal control genes and 
test them on a subset of the samples to see which gene gave less variation between 
samples. 
We wanted to generate a gene signature characteristic for tumors showing vascular 
invasion and by that signature identify tumors having an aggressive behavior. Such a 
signature might provide clinically important information for better management of the 
patients. Also, the vascular invasion signature would possibly provide an improved 
understanding of the biology involved in tumor progression and metastatic spread.  
8.1.3 Protein expression studies
Immunohistochemistry is widely used to study protein expression, distribution and 
localization in human malignancies. In Paper II, we wanted to investigate the protein 
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expression of up-regulated genes identified in the signature. Many of these genes do 
not have corresponding antibodies that are well documented, and their use requires 
validation. In most cases it is difficult to tell by IHC if an antibody binds specifically 
or not. We here used western blot to investigate the specificity of an antibody, and a 
distinct band with the predicted protein mass gives an indication that the antibody is 
specific. We also used sections of tissues known to express the investigated protein as 
positive controls, and often multi-tissue blocks containing different cancers and 
normal tissues. In Paper III, the BMI-1 protein expression was investigated using 
two different BMI-1 antibodies, one commercial and one non-commercial. The 
commercial BMI-1 antibody has been examined by our group by western blot.274 Both 
BMI-1 antibodies gave similar results on IHC which supports the reliability of the 
results. We stained TMA sections in Paper II-IV. Using TMAs, with several 
different tumors on one slide, decreased variation in the treatment between tumors is 
ensured. Paraffin blocks with several different cases are tissue, money and time 
saving. Cores in triplicate have been shown to be representative for the whole tumor 
section for several antigens.275-277  
The staining index method, including both the staining intensity and the proportion of 
tumor cells showing positive staining, was established in our laboratory and has been 
used on many cancer types and in different studies.236, 274, 278, 279 Dividing the patients 
into subgroups by using this staining index is distinctive for each antibody. Cut-points 
used are often based on median or quartiles for the staining index together with the 
size of the subgroups, number of events and survival similarities. There is no clear 
consensus on how to divide patients into subgroups, sometimes making it difficult to 
compare results from different studies. Reporting recommendations for tumor marker 
prognostic studies (REMARK) have been proposed by the National Cancer Institute 
and European Organisation for Research and Treatment of Cancer.280  
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8.1.4 Cell cultures 
Tumor-endothelial interactions can be studied by different methods. Cell and mouse 
models with endothelial cells, smooth muscle cells and matrix proteins make it 
possible to study vessel formation under the influence of external stimuli.281, 282 There 
are also systems where cells can be co-cultured and separated by a porous membrane 
that allows the passage of soluble factors.283 We decided to study tumor-endothelial 
interactions by exposing endothelial cell lines HUVEC and HMVEC to conditioned 
media from endometrial cancer cells, and study changes in gene expression by 
microarray analysis (Paper II). This is a complex experiment and there are several 
critical aspects. We used 7 different endometrial cancer cell lines, and the information 
about these cells is limited. For instance, different assays could have given us more 
information regarding the detailed phenotypes of the cancer cells. Also, there are 
critical time aspects, considering time for cancer cells to create the conditioned media, 
and the time span in which endothelial cells are incubated with the media. These time 
points were chosen based on available literature. 
8.2 DISCUSSION OF RESULTS 
Endometrial cancer is the most common malignant tumor in the female genital tract 
among women in the western world, and the incidence is increasing.42 The majority of 
endometrial cancers is diagnosed at an early stage and has a good prognosis, but 15-
20% recurs and show limited response to treatment.284 Endometrial carcinoma is a 
heterogeneous disease, both histologically and clinically. One of the major challenges 
is to identify histopathological features or tissue-based biomarkers that can predict 
aggressive subgroups. Multiple genetic changes occur during progression from 
normal to malignant cells, and these changes are largely uncharacterized. Good 
predictive and prognostic markers are important for optimal treatment and follow-up 
of the patients. 
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8.2.1 Vascular invasion 
Vascular invasion is used as a marker to identify aggressive tumors, and this feature is 
regarded as an indicator of metastatic spread already evident in the primary tumor.285
This unfavorable prognostic factor should be reported in a routine setting,24 however, 
less is known about the molecular pathogenesis and characteristics of these early steps 
of metastatic dissemination. In our studies, vascular invasion has shown to be an 
adverse prognostic factor, both by univariate and multivariate analysis. In subgroup 
analyses among endometrioid tumors, vascular invasion was significantly associated 
with poor survival (Figure 5). 
Figure 5.  
Vascular invasion is shown by univariate survival analysis to be associated with poor 
survival in A: the retrospective series (1981-1990) and B: among the endometrioid 
tumors in the same series.  
In multivariate survival analysis of vascular invasion together with standard clinico-
pathological variables, this feature was an independent prognostic factor among the 
endometrioid tumors. Details of the multivariate analysis are given in Table 3.  
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Table 3. Multivariate survival analysis (Cox’ proportional hazards regression model)
among the endometrioid endometrial cancers in the retrospective series (n=256).
In the prospective series (n=57), vascular invasion was also significantly associated 
with decreased patient survival, both by analyzing the whole series as well as the 
endometrioid subgroup. (Figure 6). In multivariate survival analysis of vascular 
invasion together with standard clinico-pathological variables, vascular invasion did 
not reach independent prognostic importance, but this is most likely due to lack of 
statistical power. Despite this, we consider vascular invasion to be a strong indicator 
of aggressive endometrial cancers. 
Variables Categories n HRa p-valueb
Vascular invasion Absent 168 1 0.001 
 Present 88 2.5  
Histological grade 1-2 172 1 <0.001 
 3 84 10.8  
FIGO stage I/II 213 1 0.001 
 III/IV 43 2.4  
aHazard Ratio, bLratio test 
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Figure 6.  
Univariate survival analysis of A: the whole prospective series, n=57 and B: the 
endometrioid endometrial tumors in relation to vascular invasion, n=51. 
In Paper I, we show that lymphatic vascular invasion occurs more frequently than 
blood vessel invasion (31% versus 18%). Our data indicate that both of these 
characteristics (LVI and BVI) are biologically important for clinical progress of 
endometrial cancer, but hematogenic spread as indicated by BVI appears to 
characterize more aggressive tumors. In cervical carcinoma, BVI has been reported to 
be associated with more aggressive phenotypes, and found to be an independent 
prognostic factor.286 Blood vessel invasion has been reported to be an independent 
factor for overall and relapse-free survival in other cancer types like node-negative 
breast cancer, colorectal cancer and urothelial carcinoma.181, 287, 288 Further, LVI has 
showed a correlation to lymph node metastasis in breast cancer, gastric cancer and 
bladder transitional cell carcinoma.289-291
8.2.2 Genes related to vascular invasion and tumor progression 
Cancer cells originate from multiple genetic alterations and cellular changes. Several 
genes are known to be involved in tumor progression, but the underlying molecular 
mechanisms that determine the metastatic potential are not fully characterized.292
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Various diseases and pathological conditions may be reflected by gene expression 
profiles, and derived signatures may be useful for prognostic consideration and for 
sub-grouping of patients.293, 294 Global gene expression patterns might improve 
disease classification and give higher efficiency in the field of cancer diagnosis.  
A gene signature consisting of 18 genes in relation to vascular invasion was identified 
in Paper II. It would have been an advantage to validate the gene signature on 
separate series of endometrial cancer, but such data were not available at the time. A 
future goal would be to expand the series significantly and derive independent 
signatures specific for BVI and LVI, with sufficient statistical power for reliable 
subgroup analysis.  
Several studies have used different models to characterize aggressive tumors and 
learn more about the underlying biological mechanisms. For instance, signatures have 
been constructed for epithelial-mesenchymal transition (EMT),295 normal tissues have 
been compared with tumor tissues,296 and metastatic and non-metastatic cancer tissues 
have been examined.297
Vascular involvement in our material was related to predefined gene sets for 
epithelial-mesenchymal transition, wound response, endothelial cells and VEGF 
activity.298-301 Taken together, these data support a relationship between activated 
angiogenesis, stroma remodeling and vascular spread as an indicator of metastatic 
disease.  
Subsequently, published gene signatures related to tumor progression were mapped to 
our data set. Our vascular invasion signature was associated with the VEGF signature 
(r=0.74, p<0.001), the BMI signature in Paper III (r=0.71, p<0.001) and the wound 
response signature (r=0.87, p<0.001), supporting that our vascular invasive signature 
may identify aggressive cancers (Figure 7).  
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Figure 7. 
The vascular invasion signature shows correlations to the published signatures for 
VEGF, BMI-1 and wound response (CSR).123, 298, 300
Our vascular invasion signature was then examined in an external dataset on breast 
cancer from Lu and collaborators,292 including information on tumor type, grade, 
tumor size, lymphatic vascular invasion, node status, ER and HER2 expression 
(n=129). A summary of the vascular invasion signature was done, and patients were 
divided into two groups by the median value. Patients with a high signature score 
showed associations to tumor type, histological grade, ER and HER2 status (Table 4). 
Survival data were not available. 
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Table 4. Associations between the vascular invasion signature (VIS) and clinico-
pathological features in 129 breast cancer patients.292
  
We then examined a public data set (NCBI GEO: GSE2109) containing 111 
endometrial cancers with information about histological type, grade and FIGO stage 
(data not available for all tumors). We mapped our 18 genes from the vascular 
invasion signature, made a summary signature and divided patients into two groups by 
the median value. Patients with a high signature score showed significant associations 
Variables Categories VIS  median 
N (%) 
VIS >median 
N (%) 
p-value 
Histological type Ductal 42 (44) 53 (56) 0.047 
 Lobular  14 (74) 5 (26)  
 Mixed 9 (60) 6 (40)  
Histological grade 1 20 (74) 7 (26) 0.002 
 3 19 (59) 13 (41)  
 3 26 (37) 44 (63)  
ER status Negative 19 (36) 34 (64) 0.006 
 Positive 46 (61) 30 (39)  
HER2 status Negative 57 (58) 41 (42) 0.002 
 Positive 8 (26) 23 (74)  
Tumor size 2 cm 31 (57) 23 (43) NS 
 >2 cm 34 (45) 41 (55)  
LVI Absent 40 (50) 40 (50) NS 
 Present 25 (51) 24 (49)  
Node status Negative 31 (48) 33 (52) NS 
 Positive 34 (52) 31 (48)  
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to histological grade (p=0.019) and a trend regarding FIGO stage (p=0.071) (Table 
5). 
Table 5. Associations between the vascular invasion signature (VIS) and clinico-
pathological features in 111 endometrial cancer patients.  
Finally, gene expression data from 230 grade 1-3 breast cancers were also examined 
in relation to our vascular invasion signature.302 We mapped our 18 genes from the 
vascular invasion signature, made a summary signature and divided patients into two 
groups by the median value. Patients with a high signature score showed significant 
associations to histological grade (p <0.001), ER (p <0.001), PR (p=0.001) and 
response to preoperative chemotherapy (p=0.001). A trend regarding HER2 (p=0.082) 
was also seen (Table 6). 
Variables Categories VI sign median 
N (%) 
VI sign >median 
N (%) 
p-value 
Histological type EECa 48 (53) 43 (47) NS 
 NEECb 8 (40) 12 (60)  
Histological Grade 1 12 (80) 3 (20) 0.019 
 2 14 (42) 19 (58)  
 3 12 (38) 20 (62)  
FIGO stage  I-II 30 (55) 25 (25) 0.071 
 III-IV 9 (33) 18 (67)  
aEndmetrioid endometrial cancer, bNon-endometrioid endometrial cancer 
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Table 6. Associations between the vascular invasion signature (VIS) and clinico-
pathological features in 230 breast cancer patients.  
The associations between our gene signature (VIS) and publicly available datasets 
from breast and endometrial cancers, and associations with aggressive clinico-
pathological phenotypes (Table 4, 5 and 6, Figure 4) provide further evidence that 
our signature might manage to identify aggressive tumors, not just endometrial 
cancers. 
Variables Categories VI sign median 
N (%) 
VI sign >median 
N (%) 
p-value 
Histological Grade 1 10 (77) 3 (23) <0.001 
 2 59 (63) 35 (37)  
 3 46 (37) 77 (63)  
ER status Negative 27 (30) 62 (70) <0.001 
  Positive 88 (62) 53 (38)   
PR status Negative 50 (40) 76 (60) 0.001 
  Positive 65 (63) 39 (37)   
HER2 status Negative 100 (53) 90 (47) 0.082 
  Positive 15 (38) 25 (62)   
Response to pre-op. pCRa 14 (29) 34 (71) 0.001 
chemotherapy RDb 101 (56) 81 (44)  
apCR: pathological complete response, no residual invasive cancer, bRD: residual invasive cancer 
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A BMI-driven signature containing 11 genes, generated from a BMI-1+/+ versus BMI-
1–/–genetic background, is suggested to have prognostic impact in several cancers.123
In Paper III, we show that the BMI-1 signature also had a prognostic impact in 
endometrial cancer, with a significant association to vascular invasion. Interestingly, 
our results in Paper III demonstrate an inverse correlation between BMI-1 mRNA 
expression and the BMI driven signature. This inverse correlation might indicate that 
BMI-1 is not directly responsible for driving the 11-gene signature in endometrial 
cancers.  Low BMI-1 gene expression shows an association to vascular invasion and 
other aggressive phenotypes in Paper III. Contrary, studies in head and neck 
squamous cancer cells showed that overexpression of BMI-1 enhances tumorigenic 
properties.303  
8.2.3 Genes expressed by endothelial cells 
Tumor-vascular interactions are important for tumor progression. Results from 
clinical trials indicate that the use of bevacizumab, a monoclonal antibody directed 
against VEGF, improves the outcome of breast cancer.304 The tumor 
microenvironment consists of tumor stroma with blood vessels, infiltrating 
inflammatory cells and a variety of associated tissue cells. Interactions between tumor 
cells and their environment are bidirectional, with tumor cells often dominating.305, 306
With focus on endothelial cell gene expression, endometrial tumor cells were 
cultured, and their medium was added to the HUVEC and HMVEC endothelial cells 
(Paper II). Microarray analysis showed two of our upregulated candidate genes, 
ANGPTL4 and MMP3, to be clearly upregulated in stimulated endothelial cells. 
ANGPTL4 has previously been described as upregulated in endothelial cells during 
hypoxia,307 but its role in tumor progression is uncertain. During angiogenesis, 
endothelial cells are expressing MMPs that cleave components of the stroma, thus 
making it possible for endothelial cells to migrate and form new vessels.308
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8.2.4 Prognostic factors 
Several prognostic factors for endometrial cancer have been published, and the impact 
of age, histological type and grade, ploidy, hormone receptor status and FIGO stage is 
well established.2 A combined panel of prognostic markers might improve the 
identification of endometrial cancers with increased risk of recurrence. In Paper II,
Collagen 8 and MMP3 showed associations with vascular invasion by protein 
expression, and ANGPTL4 and IL8 were related to survival by univariate analysis. By 
multivariate models, ANGPTL4 was an independent prognostic factor, also in the 
endometrioid subgroup. Surprisingly, lack of ANGPTL4 protein expression was 
associated with the worst survival, while strong ANGPTL4 expression was related to 
the best prognostic outcome. This is in contrast to our expectations based on mRNA 
data. There are several possible explanations for our finding: primers and antibody 
may detect different variants of the ANGPTL4 gene and protein, and there might be 
post translational regulations of ANGPTL4 mRNA. Also, vascular invasion and 
survival are different end-points. Studies on breast cancer models show that tumor 
cell derived ANGPTL4 enhances tumor cell metastasis to the lungs by disrupting 
endothelial cell-cell junctions and increasing the permeability of lung capillaries 301. 
Also, a study of Kaposi’s sarcoma showed ANGPTL4 to promote angiogenesis and 
vascular permeability.309 On the contrary, a report on 3LL and B16F0 cell lines 
indicated that ANGPTL4 prevented the metastatic process by inhibiting vascular 
activity.310 The study showed that ANGPTL4 inhibited both tumor intravasation and 
extravasation. Overexpression of ANGPTL4 in melanoma cells gives a lower capacity 
for adhesion (to fibronectin, laminin, vitronectin and BSA), migration and invasion.310
In oesophageal squamous cell carcinoma, ANGPTL4 showed a correlation with both 
LVI and BVI and seems to play an important role in metastasis through 
lymphovascular invasion. Strong ANGPTL4 expression is correlated with poor 
prognosis in this type of cancer.311 ANGPTL4 has also been shown to be important in 
keratinocytes during wound healing,312 and knock-down of ANGPTL4 gave an 
impaired migration. Thus, whether ANGPTL4 promotes or inhibits vascular leakiness 
and cancer metastasis remains unclear and might possible represent a tissue specific 
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response. Still, these experimental studies clearly support that ANGPTL4 is involved 
in cancer progression. 
IL8 is known as an angiogenesis inducer, and studies have shown that IL8 stimulates 
endothelial proliferation and capillary tube formation in vitro.313 Surprisingly, our 
results showed high IL8 protein expression to be associated with a favorable 
prognosis. This could possible indicate that IL8 is involved in a subgroup of low-
grade endometrial carcinomas. 
In Paper III, we showed that low BMI-1 expression was related to aggressive 
features in endometrial cancer. For instance, BMI-1 mRNA and protein showed a 
negative correlation to vascular invasion. Whereas several cancers have shown high 
BMI-1 expression to be associated with increased risk for metastasis, the exact 
mechanism for this relation is not known.125, 314-316 A study of colon cancers showed 
BMI-1 to be associated with distant metastasis but not with vascular invasion,317 and a 
study of normal nasopharyngeal epithelial cells showed that high BMI-1 expression 
induces an EMT-like phenotype, with PTEN as a direct target.318 BMI-1 is considered 
to be an oncogene,319 while our study indicates that BMI-1could have a suppressor 
function in certain tissue contexts. 
LCN2 is known to be up-regulated in response to inflammation,320 and increased 
levels of LCN2 has been observed in several cancers.240, 241, 243 We show in Paper IV
that LCN2 appears to be associated with tumor progression in endometrial cancers. 
Different studies have indicated LCN2 to be involved in the EMT process. In our 
series, however, LCN2 did not show any significant associations to any of the EMT 
markers included. Of the vascular markers, only VEGF-A expression showed a 
significant association with LCN2. Thus, the exact role for LCN2 in the EMT process 
seems unclear, since some studies indicate LCN2 to promote EMT,243, 248 while others 
show LCN2 to inhibit this process.321 Regarding metastasis, mammary tumor mouse 
models show conflicting results concerning the role of LCN2 in the process. One 
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study suggests LCN2 to be a potential candidate for targeted therapy, while another 
study reported that LCN2 was not a promoter for lung metastasis.322, 323 In our 
material, LCN2 expression was increased among endometrial tumors with distant 
metastasis. 
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9. CONCLUSIONS 
1. Invasion of tumor cells into the vascular systems occurs more frequently in 
lymphatic vessels than in blood vessels in endometrial cancer (Paper I).
2. Specific blood and lymphatic vascular invasion were of independent 
prognostic importance in multivariate survival analysis in our endometrial 
cancer series (Paper I). Among the endometrioid tumors, blood vessel 
invasion was independently significant. 
3. A vascular invasion signature derived in Paper II showed significant 
associations with clinico-pathological phenotype and survival. The signature 
correlates to a published VEGF signature that identifies aggressive tumors in 
several different cancer types. 
4. Published signatures showed correlations to vascular invasion in our data set 
(Paper II). Two TGF- signatures, known to be involved in EMT, an 
endothelial signature and a wound response signature were associated with 
vascular invasion.  
5. ANGPTL4 and IL8 expression showed associations to patient survival in 
Paper II. ANGPTL4 was prognostically significant by multivariate survival 
analysis and also in the endometrioid subtype. 
6. The “BMI-1 driven” signature showed an association to patient survival and 
correlations to aggressive features of endometrial cancer (Paper III). The 
signature also showed an inverse correlation to BMI-1 gene and protein 
expression (Paper III).
7. Loss of BMI-1 mRNA and protein expression was significantly associated 
with vascular invasion and ER/PR negative tumors in endometrial cancer 
(Paper III). 
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8. LCN2 expression was associated with aggressive features of endometrial 
cancer including patient survival (Paper IV).  
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10. FUTURE PERSPECTIVES
We plan to continue our work with focus on vascular invasion together with 
angiogenesis and epithelial mesenchymal transition (EMT) using cell and mouse 
models.  
Tumor growth and metastasis requires angiogenesis, a process with growth of new 
blood vessels from already existing vascular structures. Most tumors without 
angiogenesis would remain in a dormant state. This makes angiogenesis an important 
target for the control of tumor expansion and progression. The tumor 
microenvironment consists of proliferating tumor cells, tumor stroma, blood vessels, 
infiltrating inflammatory cells and a variety of associated tissue cells. Interactions 
between tumor cells and their environment are bidirectional. Many of the steps of 
metastasis rely on activities of non-tumor cells, like endothelial cells and fibroblasts. 
Interrupting tumor-host interactions that stimulate tumor growth and metastatic spread 
is of importance in cancer treatment. 
Several groups have developed in vitro and in vivo systems that mimic the formation 
of capillary networks showing many features of in vivo angiogenesis.282, 324, 325 These 
cell culture systems are composed of endothelial cells that form vascular channels, 
and interactions with other cells are studied.324 Using mouse models, tumor cells are 
implanted into immunocompromised NOD-SCID mice together with endothelial cells 
and smooth muscle cells.282, 325 After a certain time period these implants develop a 
functional vasculature.  
By using these models, it is possible to study tumor-endothelial interactions both in 
vitro and in vivo in more detail. Our future line of research would be to investigate 
how different factors affect tumor cell migration, endothelial cells and their tube 
formation, intravasation of tumor cells and metastatic spread. Of particular interest 
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are different regulators of EMT in tumor cells and their role in angiogenesis and 
metastasis. We would also explore the effects of vascular regulators like ANGPTL4, 
COL8A1 and MMP3 (from Paper II) on EMT, tumor-vascular interactions and 
metastatic spread. Identifying new molecular markers and investigating their effects 
in tumor progression could be helpful in developing improved targeted therapy.  
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11. ERRATA 
Corrections in bold: 
Introduction: Page 57, Table 5: FIGO stage I-II within VI sign >median, N (%): 25 
(25) should read: 25 (45).  
Paper I: Page 175, Materials and Methods, paragraph 3, line 3: “The median follow- 
up period for the survivors was 9 years (range 5-15 years)” should read: The median 
follow-up period for the survivors was 17 years (range 6-23 years).  
Paper I: Page 175, Materials and Methods, paragraph 3, line 6: “Among the 117 
patients who died during the follow-up period, 70 patients died from endometrial 
carcinoma, while 47 died from other causes” should read: Among the 165 patients 
who died during the follow-up period, 74 patients died from endometrial carcinoma, 
while 91 died from other causes. 
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